Disease · MONDO_0005375

nasopharyngeal neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. nasopharyngeal neoplasm. Diseases, record MONDO_0005375. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005375

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: nasopharyngeal neoplasm; Open Targets
Open Targets ID: MONDO_0005375; Open Targets
Other names: nasopharyngeal neoplasms, nasopharyngeal tumor, nasopharyngeal tumour, nasopharynx neoplasm, nasopharynx neoplasm (disease), nasopharynx tumor, nasopharynx tumour, neoplasm of nasopharynx, neoplasm of the nasopharynx, tumor of nasopharynx, tumor of the nasopharynx, tumour of nasopharynx, tumour of the nasopharynx; Open Targets
MeSH: D009303; MeSH
NCI Thesaurus: C3257; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 13 drugs, from FDA; Open Targets

Drugs13

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SOTAGLIFLOZIN	CHEMBL3039507	Small molecule	Approval	FDA	1	0	0	Drugs and targets
NIMOTUZUMAB	CHEMBL2108359	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 13

See all 13 drugs

Targets36

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
IL6	Interleukin-6	1	Interleukin-6 binding agent; Interleukin-6 inhibitor	Unknown	https://conductscience.org/library/genes/3569	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5426	Drugs and targets

1 to 10 of 36

See all 36 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00603915	A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer	Phase 2	20	2011-08-10	Nasopharyngeal Cancer	CARBOPLATIN, CISPLATIN, ERLOTINIB, GEMCITABINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01074021	Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer	Phase 3	480		Nasopharyngeal Cancer	NIMOTUZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01312311	Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer	Phase 2	51		Nasopharyngeal Cancer	CISPLATIN, DOCETAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05305131	Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer	Phase 2	50		Nasopharyngeal Cancer	BEVACIZUMAB, CISPLATIN, GEMCITABINE, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04875611	Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment	Phase 2	32		Nasopharyngeal Cancer	NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00439426	A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.	Phase 2	25		Nasopharyngeal Cancer	CAPECITABINE, OXALIPLATIN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
21358293	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005375

GET https://conductscience.org/api/diseases/v1/MONDO_0005375/targets?page=2

API reference For AI assistants